ClinicalTrials.gg
Not yet recruitingNCT07547449Updated Apr 23, 2026

Bachmann Bundle Pacing for Prevention of New-Onset Atrial Fibrillation in Patients With Heart Failure

An interventional study of Bachmann Bundle Pacing and Right Atrial Appendage Pacing in Heart Failure, Atrial Fibrillation (AF) and Cardiac Insufficiency, sponsored by Fu Wai Hospital, Beijing, China. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Fu Wai Hospital, Beijing, China · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
119th of 247
140 · median 130
Started
2026
with 42 others
No phase
115 of 377
51 open now
Primary completion
2028-04
later than 135 of 181 live
Registered
345th of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 119th largest by planned enrollment of the 247 interventional ones that give a count, is one of 43 that started in 2026, is one of 115 with no phase, reaches primary completion later than 135 of the 181 other live ones, and was the 345th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, prospective, single-blind, randomized controlled clinical trial to evaluate the efficacy and safety of Bachmann bundle pacing (BBP) in preventing new-onset atrial fibrillation (AF) in patients with chronic cardiac insufficiency who have indications for cardiac resynchronization therapy with left bundle branch pacing (CRT/LBBP) or implantable cardioverter defibrillator (ICD) implantation.

A total of 110 eligible patients will be randomly assigned 1:1 to the BBP group or the traditional right atrial appendage (RAA) pacing group. All patients will receive guideline-directed medical therapy (GDMT) for at least 3 months and standardized follow-up for 12 months after device implantation. The primary endpoint is the incidence of new-onset AF within 12 months after implantation. Secondary endpoints include time to first new-onset AF, procedural success rate, changes in cardiac function parameters, and incidence of adverse events. This study aims to provide high-level evidence-based medical evidence for BBP as a new atrial pacing strategy to prevent AF in heart failure patients.

Read the detailed description

Background Chronic heart failure (HF) is a prevalent and prognostically poor cardiovascular disorder, with atrial fibrillation (AF) being the most common arrhythmia comorbid with HF. The bidirectional interaction between HF and AF forms a vicious cycle, significantly elevating the risks of mortality, hospitalization, and stroke in affected patients. Epidemiological data indicate that the cumulative incidence of AF following pacemaker implantation reaches 30-40%, a rate markedly higher than that in the general population without pacemaker implantation.

Traditional right atrial appendage (RAA) pacing, the most widely used clinical atrial pacing approach, induces prolonged interatrial conduction, asynchronous atrial contraction, and hemodynamic perturbations, which predispose patients to AF. The Bachmann bundle represents the most physiological atrial pacing site; pacing in this region achieves synchronous activation of the left and right atria, producing a narrower P wave compared with sinus rhythm and traditional RAA pacing. While prior studies have suggested that Bachmann bundle pacing (BBP) may reduce the recurrence and progression of atrial arrhythmias, there remains a paucity of prospective randomized controlled trials investigating the efficacy of BBP in preventing new-onset AF in HF patients undergoing cardiac resynchronization therapy with left bundle branch pacing (CRT/LBBP) or implantable cardioverter defibrillator (ICD) implantation.

Study Objectives The primary objective of this study is to determine whether BBP reduces the incidence of new-onset AF within 12 months of device implantation, compared with traditional RAA pacing, in HF patients with indications for CRT/LBBP or ICD implantation. Secondary objectives include evaluating the impact of BBP on the time to first new-onset AF, procedural safety, cardiac function parameters, electrophysiological indices, and clinical adverse events (including HF rehospitalization, all-cause death, and stroke) during the 12-month follow-up period.

Study Procedures

  1. Screening and Baseline Assessment Eligible patients are identified per predefined inclusion and exclusion criteria. Following written informed consent, baseline data are collected, including demographic characteristics, medical history, 12-lead electrocardiogram (ECG), 24-hour Holter monitoring, transthoracic echocardiography, New York Heart Association (NYHA) functional classification, 6-minute walk test results, and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.
  2. Randomization Patients are stratified by implant device type (CRT/LBBP or ICD) and randomized in a 1:1 ratio to the BBP group or the RAA pacing group via a central randomization system.
  3. Intervention Patients in the BBP group undergo atrial lead implantation at the Bachmann bundle region, identified via anatomical localization and intracardiac electrogram recording. Successful BBP is defined by characteristic ECG changes: a positive P wave in leads I, II, III, and aVF; a biphasic or negative P wave in lead V1; a P wave duration narrowed by >10 ms compared with baseline (in patients with pre-existing interatrial block); and documentation of the Bachmann bundle potential. If BBP implantation fails, the patient is immediately converted to RAA pacing, with the cause of failure recorded in detail. Intraoperative pacing parameters (threshold, sensing, impedance) are monitored in both groups.
  4. Follow-up All patients undergo follow-up assessments at 1 week, 3 months, 6 months, 9 months, and 12 months post-implantation. Follow-up evaluations include ECG, 24-hour Holter monitoring, pacemaker programming, echocardiography, NYHA classification reassessment, 6-minute walk test, NT-proBNP measurement, medication adjustment tracking, and adverse event reporting.
  5. Statistical Analysis All data are analyzed in accordance with the intention-to-treat (ITT) principle. The primary endpoint is compared using analysis of covariance, and the time to first new-onset AF is evaluated via the Kaplan-Meier method with log-rank testing. Continuous variables are compared using the t-test or Wilcoxon rank-sum test, while categorical variables are analyzed with the chi-square test or Fisher's exact test. A two-sided P value \< 0.05 is considered statistically significant.
03

Conditions studied

  • Heart Failure
  • Atrial Fibrillation (AF)
  • Cardiac Insufficiency

Keywords

  • Bachmann Bundle Pacing
  • Right Atrial Appendage Pacing
  • Cardiac Resynchronization Therapy
  • Implantable Cardioverter Defibrillator
  • Physiological Pacing
  • New-Onset Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged between 18 and 70 years old;
  2. Diagnosis of chronic cardiac insufficiency according to current guidelines, and received guideline-directed medical therapy (GDMT) for at least 3 months;
  3. Have indications for CRT/LBBP or ICD implantation, and expected atrial pacing ratio > 20%, including: Sinus rhythm, QRS duration > 120ms, LBBB, ≤ 35% with symptomatic heart failure; Sinus rhythm, QRS duration ≥ 150ms, non-LBBB, LVEF ≤ 35% with symptomatic heart failure; Sinus rhythm, QRS duration > 120ms, LBBB, LVEF 36%-50% with symptomatic heart failure; Symptomatic heart failure with LVEF ≤ 50% and expected ventricular pacing ratio > 20%; Symptomatic heart failure with LVEF ≤ 50% requiring ICD implantation for primary or secondary sudden death prevention, with atrial pacing indication due to sinus bradycardia or expected atrial pacing ratio > 20%;
  4. Patients with pacing-induced cardiomyopathy requiring upgrade therapy, in sinus rhythm, and requiring reimplantation of atrial lead;
  5. Signed written form approved by the ethics committee.

Exclusion criteria

Exclusion Criteria:

  1. Expected survival time less than 12 months;
  2. Status after mechanical tricuspid valve replacement, or congenital heart disease (including dextrocardia, transposition of great arteries, single left persistent superior vena cava);
  3. Previous history of atrial fibrillation;
  4. Previous cardiac surgery, or requiring surgical treatment for severe structural heart disease within 1 year;
  5. Pregnancy, planned pregnancy, or heart transplantation;
  6. Patient refusal to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Bachmann Bundle Pacing

    Patients receive atrial lead implantation at the Bachmann bundle region, identified by anatomical localization and intracardiac electrogram. Successful BBP is defined by characteristic ECG changes (positive P wave in I/II/III/aVF, biphasic/negative P wave in V1, narrowed P wave duration) and recording of Bachmann bundle potential. If BBP fails, patients are converted to RAA pacing, with failure reasons documented.

    Procedure: Bachmann Bundle Pacing

  • Active comparator
    Traditional Right Atrial Appendage Pacing

    Patients receive conventional atrial lead implantation in the right atrial appendage (RAA), the standard clinical atrial pacing method. Intraoperative pacing parameters (threshold, sensing, impedance) are monitored identically to the experimental group to ensure normal pacing function. All patients continue guideline-directed medical therapy for heart failure throughout the study.

    Procedure: Right Atrial Appendage Pacing

Interventions

  • ProcedureBachmann Bundle Pacing

    A minimally invasive endocardial pacing procedure where an atrial lead is placed at the Bachmann bundle region (located at the junction of the right atrium and left atrial appendage) under fluoroscopic and intracardiac electrogram guidance. Successful implantation is confirmed by characteristic ECG changes (positive P wave in leads I/II/III/aVF, biphasic/negative P wave in V1, P wave duration reduction \>10 ms in patients with interatrial block) and recording of the Bachmann bundle potential.

    Also known as: BBP

  • ProcedureRight Atrial Appendage Pacing

    The standard clinical atrial pacing procedure where an atrial lead is implanted in the right atrial appendage via transvenous access, guided by fluoroscopy. Pacing parameters (threshold, sensing, impedance) are optimized intraoperatively to ensure stable atrial capture, consistent with current clinical practice guidelines for cardiac pacing in heart failure patients.

    Also known as: RAA Pacing

06

What researchers measure

Primary outcomes

  1. Incidence of New-Onset Atrial Fibrillation

    The proportion of patients who develop new-onset atrial fibrillation (AF) confirmed by 12-lead ECG or 24-hour Holter monitoring within 12 months after cardiac pacing device implantation. New-onset AF is defined as the first documentation of AF with a duration ≥30 seconds in patients with no prior history of AF or paroxysmal AF (documented ≥3 months before enrollment).

    Time frame: 12 months after device implantation

  2. Time to Onset of New-Onset Atrial Fibrillation Post-Device Implantation

    Time from CRT/LBBP or ICD implantation to the first documentation of new-onset atrial fibrillation (AF) confirmed by 12-lead ECG or 24-hour Holter monitoring, with AF defined as an episode lasting ≥30 seconds. Time is recorded in days and analyzed using Kaplan-Meier survival methods.

    Time frame: Up to 12 months after device implantation

Secondary outcomes

  1. Immediate Success Rate of Bachmann Bundle Pacing and Perioperative Complication Rate

    Immediate success of Bachmann bundle pacing is defined as stable lead placement with successful atrial capture and characteristic ECG changes intraoperatively; perioperative complications (occurring within 30 days post-surgery) include lead dislodgement, pneumothorax, cardiac tamponade, and pocket hematoma, with incidence calculated as the proportion of patients with at least one complication in each group.

    Time frame: Intraoperatively (success rate) and 30 days post-implantation (perioperative complications)

  2. Absolute and percentage change in left atrial diameter/volume index from baseline to 12 months

    Absolute and percentage changes in left atrial diameter (mm) and left atrial volume index (mL/m²) measured by transthoracic echocardiography at 12 months post-implantation compared with baseline.

    Time frame: Baseline and 12 months after device implantation

  3. Change in mitral/tricuspid regurgitation grade from baseline to 12 months

    Change in mitral and tricuspid regurgitation grade (graded 0-IV) measured by transthoracic echocardiography at 12 months post-implantation compared with baseline.

    Time frame: Baseline and 12 months after device implantation

  4. Absolute change in left ventricular end-diastolic diameter (LVEDD) from baseline to 12 months

    Absolute change in LVEDD (mm) measured by transthoracic echocardiography at 12 months post-implantation compared with baseline.

    Time frame: Baseline and 12 months after device implantation

  5. Absolute change in left ventricular end-systolic volume (LVESV) from baseline to 12 months

    Absolute change in LVESV (mL) measured by transthoracic echocardiography at 12 months post-implantation compared with baseline.

    Time frame: Baseline and 12 months after device implantation

  6. Change in New York Heart Association (NYHA) functional class from baseline to 12 months

    Change in NYHA functional class (graded I-IV) at 12 months post-implantation compared with baseline.

    Time frame: Baseline and 12 months after device implantation

  7. Absolute change in 6-minute walk test (6MWT) distance from baseline to 12 months

    Absolute change in 6MWT distance (meters) at 12 months post-implantation compared with baseline

    Time frame: Baseline and 12 months after device implantation

  8. Absolute change in plasma NT-ProBNP level from baseline to 12 months

    Absolute change in plasma NT-ProBNP level (pg/mL) measured by chemiluminescent immunoassay at 12 months post-implantation compared with baseline.

    Time frame: Baseline and 12 months after device implantation

  9. Comparison of P-wave duration from baseline to 12 months

    Comparison of P-wave duration (ms) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation

    Time frame: Baseline and 12 months after device implantation

  10. Comparison of P-wave amplitude from baseline to 12 months

    Comparison of P-wave amplitude (mV) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation

    Time frame: Baseline and 12 months after device implantation

  11. Comparison of P-wave vector from baseline to 12 months

    Comparison of P-wave vector in the supine position between baseline and 12 months post-implantation.

    Time frame: Baseline and 12 months after device implantation

  12. Prevalence of interatrial block at baseline and 12 months

    Prevalence of interatrial block (diagnosed by ECG criteria) in the supine position between baseline and 12 months post-implantation

    Time frame: Baseline and 12 months after device implantation

  13. Comparison of ventricular pacing threshold from baseline to 12 months

    Comparison of ventricular pacing threshold (V) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation.

    Time frame: Baseline and 12 months after device implantation

  14. Comparison of sensing threshold from baseline to 12 months

    Comparison of sensing threshold (mV) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation

    Time frame: Baseline and 12 months after device implantation

  15. Comparison of lead impedance from baseline to 12 months

    Comparison of lead impedance (Ω) in the supine position (mean of 3 consecutive readings) between baseline and 12 months post-implantation.

    Time frame: Baseline and 12 months after device implantation

  16. Incidence of Procedure Complications Within 12 Months Post-Implantation

    Cumulative incidence of long-term surgical complications (including lead fracture, chronic pocket infection, lead dislodgement, and cardiac perforation) within 12 months post-implantation, with complications adjudicated by an independent committee using VARC-3 criteria for severity and causality.

    Time frame: 12 months after device implantation

  17. Incidence of Heart Failure Rehospitalization, All-Cause Death, and Stroke Within 12 Months

    Cumulative incidence of heart failure rehospitalization (unplanned admission for worsening HF), all-cause mortality, and ischemic/hemorrhagic stroke within 12 months post-implantation. All events are documented via medical records and confirmed by the study team.

    Time frame: 12 months after device implantation

07

Study locations

1 site
  • Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100037, China
08

References and documents

Publications

  • Subramanian M, Yalagudri S, Saggu D, Singh J, Bootla D, Krishnamoorthy P, Chennapragda S, Narasimhan C. Electrogram-guided Bachmann bundle area pacing to correct interatrial block: Initial experience, safety, and feasibility. Heart Rhythm. 2025 Apr;22(4):1064-1070. doi: 10.1016/j.hrthm.2024.08.024. Epub 2024 Aug 20. PubMed 39168297 ↗
  • Lustgarten DL, Habel N, Sanchez-Quintana D, Winget J, Correa de Sa D, Lobel R, Thompson N, Infeld M, Meyer M. Bachmann bundle pacing. Heart Rhythm. 2024 Sep;21(9):1711-1717. doi: 10.1016/j.hrthm.2024.03.1786. Epub 2024 Mar 27. No abstract available. PubMed 38552731 ↗
  • Infeld M, Nicoli CD, Meagher S, Tompkins BJ, Wayne S, Irvine B, Betageri O, Habel N, Till S, Lobel J, Meyer M, Lustgarten DL. Clinical impact of Bachmann's bundle pacing defined by electrocardiographic criteria on atrial arrhythmia outcomes. Europace. 2022 Oct 13;24(9):1460-1468. doi: 10.1093/europace/euac029. PubMed 35304608 ↗
  • Bailin SJ, Adler S, Giudici M. Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: results of a multicenter randomized trial. J Cardiovasc Electrophysiol. 2001 Aug;12(8):912-7. doi: 10.1046/j.1540-8167.2001.00912.x. PubMed 11513442 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — The decision to share individual participant data (IPD) is currently undecided and will be reassessed upon completion of the study. Considerations will include compliance with Chinese regulations on medical data privacy, ethical approval requirements for data sharing, and the need to protect participants' confidential health information. A formal IPD sharing plan will be developed if deemed appropriate post-study, in accordance with international clinical research standards.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 24 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 23, 2026
StartEst.
Apr 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07547449
Lead sponsor
Fu Wai Hospital, Beijing, China
Responsible party
Xiaohan Fan (Chief Physician, Fu Wai Hospital, Beijing, China) — Principal investigator
First posted
Apr 23, 2026
Start date
Apr 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Apr 23, 2026

Study contacts

Xiaohan Fan, MD, PhD
Contact
fanxiaohan@fuwaihospital.org
+8615611980322

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion